Evaluation and Treatment of Endoplasmic Reticulum (ER) Stress in Right Ventricular Dysfunction during Monocrotaline-Induced Rat Pulmonary Arterial Hypertension

Cardiovascular Drugs and Therapy

Volumn 30, Issue 6, 2016, Pages 587-598

  Wang, Jing Jing ^a   Zuo, Xiang Rong ^a   Xu, Jian ^a   Zhou, Jin Yong ^b   Kong, Hui ^a   Zeng, Xiao Ning ^a   Xie, Wei Ping ^a   Cao, Quan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Endoplasmic reticulum (ER) stress; Inflammation; Pulmonary artery hypertension; Right ventricular dysfunction

Indexed keywords

4 PHENYLBUTYRIC ACID; ACTIVATING TRANSCRIPTION FACTOR 6; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; GLUCOSE REGULATED PROTEIN 78; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 6; MESSENGER RNA; PROTEIN IRE1; PROTEIN KINASE RNA LIKE ENDOPLASMIC RETICULUM KINASE; REGULATOR OF CALCINEURIN 1; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; X BOX BINDING PROTEIN 1; 4-PHENYLBUTYRIC ACID; ARYLBUTYRIC ACID DERIVATIVE; ATF6 PROTEIN, RAT; BRAIN NATRIURETIC PEPTIDE; DDIT3 PROTEIN, RAT; ERN2 PROTEIN, RAT; HEAT SHOCK PROTEIN; HSPA5 PROTEIN, RAT; MEMBRANE PROTEIN; MONOCROTALINE; PEPTIDE FRAGMENT; PERK KINASE; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); PROTEIN KINASE R; PROTEIN SERINE THREONINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CAPILLARY DENSITY; CARDIAC MUSCLE CELL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENDOPLASMIC RETICULUM STRESS; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MALE; MONOCROTALINE-INDUCED PULMONARY HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HEART VENTRICLE; HYPERTENSION, PULMONARY; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACTIVATING TRANSCRIPTION FACTOR 6; ANIMALS; APOPTOSIS; EIF-2 KINASE; ENDOPLASMIC RETICULUM STRESS; HEART VENTRICLES; HEAT-SHOCK PROTEINS; HYPERTENSION, PULMONARY; MALE; MEMBRANE PROTEINS; MONOCROTALINE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PHENYLBUTYRATES; PROTEIN-SERINE-THREONINE KINASES; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TRANSCRIPTION FACTOR CHOP; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 84995466607     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-016-6702-1     Document Type: Article

References (39)

1. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53:1573–619.
2. Rhodes CJ, Davidson A, Gibbs JS, et al. Therapeutic targets in pulmonary arterial hypertension. Pharmacol Ther. 2009;121:69–88.
3. Rasmussen JT, Thenappan T, Benditt DG, et al. Is cardiac resynchronization therapy for right ventricular failure in pulmonary arterial hypertension of benefit? Pulm Circ. 2014;4:552–9.
4. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J. 2010;159:245–57.
5. Fox BD, Shimony A, Langleben D. Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. Am J Cardiol. 2011;108:1177–82.
6. Coeytaux RR, Schmit KM, Kraft BD, et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. Chest. 2014;145:1055–63.
7. Voelkel NF, Quaife RA, Leinwand LA, et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation. 2006;114:1883–91.
8. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156–63.
9. van de Veerdonk MC, Kind T, Marcus JT, et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. J Am Coll Cardiol. 2011;58:2511–9.
10. van Wolferen SA, Marcus JT, Boonstra A, et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J. 2007;28:1250–7.
11. Tan XY, He JG. The remodeling of connexin in the hypertrophied right ventricular in pulmonary arterial hypertension and the effect of a dual ET receptor antagonist (bosentan). Pathol Res Pract. 2009;205:473–82.
12. Bogaard HJ, Natarajan R, Mizuno S, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med. 2010;182:652–60.
13. Kojonazarov B, Sydykov A, Pullamsetti SS, et al. Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. Int J Cardiol. 2013;167:2630–7.
14. Bogaard HJ, Natarajan R, Henderson SC, et al. Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation. 2009;120:1951–60.
15. Dore A, Houde C, Chan KL, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112:2411–6.
16. Vonk-Noordegraaf A, Haddad F, Chin KM, et al. Right heart adaptation to pulmonary arterial hypertension: physiology and pathobiology. J Am Coll Cardiol. 2013;62:D22–33.
17. Groenendyk J, Sreenivasaiah PK. Kim do H, et al. biology of endoplasmic reticulum stress in the heart. Circ Res. 2010;107:1185–97.
18. Minamino T, Komuro I, Kitakaze M. Endoplasmic reticulum stress as a therapeutic target in cardiovascular disease. Circ Res. 2010;107:1071–82.
19. Minamino T, Kitakaze M. ER stress in cardiovascular disease. J Mol Cell Cardiol. 2010;48:1105–10.
20. Yeager ME, Reddy MB, Nguyen CM, et al. Activation of the unfolded protein response is associated with pulmonary hypertension. Pulm Circ. 2012;2:229–40.
21. Dromparis P, Paulin R, Stenson TH, et al. Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation. 2013;127:115–25.
22. Koyama M, Furuhashi M, Ishimura S, et al. Reduction of endoplasmic reticulum stress by 4-phenylbutyric acid prevents the development of hypoxia-induced pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2014;306:H1314–23.
23. Guihaire J, Bogaard HJ, Flecher E, et al. Experimental models of right heart failure: a window for translational research in pulmonary hypertension. Semin Respir Crit Care Med. 2013;34:689–99.
24. Zuo XR, Wang Q, Cao Q, et al. Nicorandil prevents right ventricular remodeling by inhibiting apoptosis and lowering pressure overload in rats with pulnary arterial hypertension. PLoS One. 2012;7:e44485.
25. Li P, Kondo T, Numaguchi Y, et al. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension. 2008;51:252–8.
26. Ko JH, Eom GH, Cho HJ, et al. Right ventricular myocardial performance index is decreased with severe pressure-overload cardiac hypertrophy in young rats. Pediatr Cardiol. 2013;34:1556–66.
27. Kawahara Y, Tanonaka K, Daicho T, et al. Preferable anesthetic conditions for echocardiographic determination of murine cardiac function. J Pharmacol Sci. 2005;99:95–104.
28. Chaudhari N, Talwar P, Parimisetty A, et al. A molecular web: endoplasmic reticulum stress, inflammation, and oxidative stress. Front Cell Neurosci. 2014;8:213.
29. Campian ME, Hardziyenka M, de Bruin K, et al. Early inflammatory response during the development of right ventricular heart failure in a rat model. Eur J Heart Fail. 2010;12:653–8.
30. Jager R, Bertrand MJ, Gorman AM, et al. The unfolded protein response at the crossroads of cellular life and death during endoplasmic reticulum stress. Biol Cell. 2012;104:259–70.
31. Belmont PJ, Tadimalla A, Chen WJ, et al. Coordination of growth and endoplasmic reticulum stress signaling by regulator of calcineurin 1 (RCAN1), a novel ATF6-inducible gene. J Biol Chem. 2008;283:14012–21.
32. Yap LB, Mukerjee D, Timms PM, et al. Natriuretic peptides, respiratory disease, and the right heart. Chest. 2004;126:1330–6.
33. Pai RK, Kedia A, Hsu PY, et al. The use of the Doppler pulmonary artery velocity time integral to optimize placement of a ventricular pacing lead in a patient with Ebstein's anomaly. J Interv Card Electrophysiol. 2004;11:55–7.
34. Reddy RK, Mao C, Baumeister P, et al. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem. 2003;278:20915–24.
35. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012;13:89–102.
36. Toko H, Takahashi H, Kayama Y, et al. ATF6 is important under both pathological and physiological states in the heart. J Mol Cell Cardiol. 2010;49:113–20.
37. Martindale JJ, Fernandez R, Thuerauf D, et al. Endoplasmic reticulum stress gene induction and protection from ischemia/reperfusion injury in the hearts of transgenic mice with a tamoxifen-regulated form of ATF6. Circ Res. 2006;98:1186–93.
38. Wu J, Rutkowski DT, Dubois M, et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev Cell. 2007;13:351–64.
39. Jones JE, Mendes L, Rudd MA, et al. Serial noninvasive assessment of progressive pulmonary hypertension in a rat model. Am J Physiol Heart Circ Physiol. 2002;283(1):H364–71.